MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- IPCA LABORATORIES LIMITED (pharmaceuticals)
- Latest 8 Quarter Result
IPCA Labs Quarterly Results (IPLB)
Here are the latest quarterly results of IPCA Labs. For more details, see the IPCA Labs financial fact sheet and IPCA Labs share price and chart. For a sector overview, read our pharmaceuticals sector report.
IPCA Labs Quarterly Results
| No. of Mths Qtr. Ending |
3
Sep-18 |
3
Dec-18 |
3
Mar-19 |
3
Jun-19 |
3
Sep-19 |
3
Dec-19 |
3
Mar-20 |
3
Jun-20 |
8-Qtr Chart Click to enlarge |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 9,978 | 9,476 | 8,338 | 10,110 | 12,126 | 11,391 | 10,048 | 14,853 | |
| Other income | Rs m | 138 | 126 | 146 | 194 | 143 | 176 | 133 | 117 | |
| Turnover | Rs m | 10,116 | 9,602 | 8,484 | 10,304 | 12,269 | 11,567 | 10,181 | 14,969 | |
| Expenses | Rs m | 8,250 | 7,159 | 6,591 | 8,160 | 9,510 | 8,736 | 8,121 | 8,973 | |
| Gross profit | Rs m | 1,728 | 2,317 | 1,747 | 1,950 | 2,616 | 2,654 | 1,927 | 5,880 | |
| Depreciation | Rs m | 432 | 426 | 416 | 420 | 451 | 462 | 454 | 452 | |
| Interest | Rs m | 24 | 49 | 63 | 45 | 41 | 38 | 35 | 25 | |
| Profit before tax | Rs m | 1,410 | 1,968 | 1,414 | 1,680 | 2,267 | 2,331 | 1,572 | 5,519 | |
| Tax | Rs m | 213 | 366 | 319 | 359 | 307 | 365 | 294 | 983 | |
| Profit after tax | Rs m | 1,197 | 1,602 | 1,095 | 1,321 | 1,960 | 1,966 | 1,278 | 4,536 | |
| Gross profit margin | % | 17.3 | 24.5 | 20.9 | 19.3 | 21.6 | 23.3 | 19.2 | 39.6 | |
| Effective tax rate | % | 15.1 | 18.6 | 22.6 | 21.4 | 13.5 | 15.6 | 18.7 | 17.8 | |
| Net profit margin | % | 12.0 | 16.9 | 13.1 | 13.1 | 16.2 | 17.3 | 12.7 | 30.5 | |
| Diluted EPS | Rs | 9.5 | 12.7 | 8.7 | 10.5 | 15.5 | 15.6 | 10.1 | 35.9 | |
| Diluted EPS (TTM) | Rs | 27.1 | 31.4 | 36.0 | 41.3 | 47.4 | 50.3 | 51.7 | 77.2 | |
 Subscriber Feature |
||||||||||
Interim results exclude extraordinary / exceptional items
Read: IPCA Labs 1QFY21 Result Performance Review
More Pharmaceuticals Company Quarterly Results: ALKEM LABORATORIES AJANTA PHARMA STRIDES PHARMA SCIENCE CADILA HEALTHCARE WYETH
Compare IPCA LABS With: ALKEM LABORATORIES AJANTA PHARMA STRIDES PHARMA SCIENCE CADILA HEALTHCARE WYETH
Compare IPCA LABS With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Today's Market
Sensex Opens Higher; Telecom and Consumer Durable Stocks Lead(09:30 am)
Asian stock markets are trading on a mixed note today after positive US economic data and signs of progress in stimulus talks in Washington lifted Wall Street benchmarks.
Views on news
IPCA LABS Announces Quarterly Results (1QFY21); Net Profit Up 243.5% (Quarterly Result Update)
Sep 29, 2020 | Updated on Sep 29, 2020For the quarter ended June 2020, IPCA LABS has posted a net profit of Rs 5 bn (up 243.5% YoY). Sales on the other hand came in at Rs 15 bn (up 46.9% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.
IPCA LABS Announces Quarterly Results (3QFY20); Net Profit Up 22.8% (Quarterly Result Update)
Feb 17, 2020 | Updated on Feb 17, 2020For the quarter ended December 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 22.8% YoY). Sales on the other hand came in at Rs 11 bn (up 20.2% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.
More Views on NewsMost Popular
The 'Seedhi Baat, No Bakwaas' View on ITC (Profit Hunter)
Oct 12, 2020Is ITC an investment or a speculation at current levels?
One of the Best Investment Opportunities in the Market Right Now (Fast Profits Daily)
Oct 16, 2020The one sector that you should be looking at to make good profits.
PSU Stocks Are Looking Positive Now (Fast Profits Daily)
Oct 19, 2020Has the market changed its opinion on PSUs?
Why India's Drone Revolution is a 4x Profit Opportunity (Profit Hunter)
Oct 16, 2020My research on India's leading defence companies brought me to one major player in drone manufacturing.
MoreOUR TOP 5 IDEAS
- Free Report: Multibagger Stock Ideas 2021
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
IPCA LABS SHARE PRICE
Oct 23, 2020 10:04 AM
TRACK IPCA LABS
- Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON IPCA LABS
IPCA LABS - TEVA PHARMA COMPARISON
COMPARE IPCA LABS WITH
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.